AAAAAA

   
Results: 1-8 |
Results: 8
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
Authors: Kelly, WK Curley, T Slovin, S Heller, G McCaffrey, J Bajorin, D Ciolino, A Regan, K Schwartz, M Kantoff, P George, D Oh, W Smith, M Kaufman, D Small, EJ Schwartz, L Larson, S Tong, W Scher, H
Citation: Wk. Kelly et al., Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer, J CL ONCOL, 19(1), 2001, pp. 44-53
The collection of indirect and nonmedical direct costs (COIN) form - A newtool for collecting the invisible costs of androgen independent prostate carcinoma
Authors: Sherman, EJ Pfister, DG Ruchlin, HS Rubin, DM Radzyner, MH Kelleher, GH Slovin, SF Kelly, WK Scher, HI
Citation: Ej. Sherman et al., The collection of indirect and nonmedical direct costs (COIN) form - A newtool for collecting the invisible costs of androgen independent prostate carcinoma, CANCER, 91(4), 2001, pp. 841-853
The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer
Authors: Kelly, WK Osman, I Reuter, VE Curley, T Heston, WDW Nanus, DM Scher, HI
Citation: Wk. Kelly et al., The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer, CLIN CANC R, 6(3), 2000, pp. 838-846
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer
Authors: Zelefsky, MJ Kelly, WK Scher, HI Lee, H Smart, T Metz, E Schwartz, L Fuks, Z Leibel, SA
Citation: Mj. Zelefsky et al., Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer, J CL ONCOL, 18(9), 2000, pp. 1936-1941
Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
Authors: Dodd, PM McCaffrey, JA Hilton, S Mazumdar, M Herr, H Kelly, WK Icasiano, E Boyle, MG Bajorin, DF
Citation: Pm. Dodd et al., Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract, J CL ONCOL, 18(4), 2000, pp. 840-846
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
Authors: Small, EJ Frohlich, MW Bok, R Shinohara, K Grossfeld, G Rozenblat, Z Kelly, WK Corry, M Reese, DM
Citation: Ej. Small et al., Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer, J CL ONCOL, 18(21), 2000, pp. 3595-3603
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract - Final report of a phase II trial evaluating two dosing schedules
Authors: Bajorin, DF McCaffrey, JA Dodd, PM Hilton, S Mazumdar, M Kelly, WK Herrr, H Scher, HI Icasiano, E Higgins, G
Citation: Df. Bajorin et al., Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract - Final report of a phase II trial evaluating two dosing schedules, CANCER, 88(7), 2000, pp. 1671-1678
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
Authors: Sabbatini, P Larson, SM Kremer, A Zhang, ZF Sun, M Yeung, H Imbriaco, M Horak, I Conolly, M Ding, C Ouyang, P Kelly, WK Scher, HI
Citation: P. Sabbatini et al., Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer, J CL ONCOL, 17(3), 1999, pp. 948-957
Risultati: 1-8 |